Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T-cell Therapy + Utomilumab in Ovarian Cancer
NCT03318900Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of utomilumab, IL-21-primed autologous CD8-positive T-lymphocytes in ovarian cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2018; status: completed.
02
Drugs
utomilumabIL-21-primed autologous CD8-positive T-lymphocytes
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03318900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318900.